Home / Letter From The Editor (page 5)

Letter From The Editor

Nov. 16, 2019

Whenever you look at the slide from the international diabetes center that shows the progression to diabetes, there is always an arrow pointing to the decline in insulin production as resistance increases. Supposedly fixing this problem was the target of the first oral diabetes medication, chlorpropamide, which became available in …

Read More »

Nov. 12, 2019

Many times our patients survive their diabetes by finding substitutions for foods they just can’t live without. They will find breads made of cauliflower, candies made from nuts and syrups that replace sugar with non-caloric artificial sweeteners. Just a quick look at YouTube will show thousands of these tricks. However …

Read More »

Nov. 9, 2019

Medication persistence gets a lot of attention these days, as we all have seen patients discontinue or miss doses of chronic medications. Sometimes it is the pill burden, and for others it is the multiple copays for all the medications they get from the pharmacy. If you add the burden …

Read More »

Nov. 5, 2019

Last week I was watching an episode of the show New Amsterdam and they had an ER patient who was in DKA because they couldn’t afford their insulin. The medical director made a big deal and said they would make their own. The first thing that came to my mind …

Read More »

Nov. 2, 2019

We have covered a lot of articles featuring the use of intermittent fasting. The term gets used in many ways and makes no distinction between only eating for a limited time every day or alternating days of no eating with eating. For a lot of patients, the every other day …

Read More »

Oct. 29, 2019

I have been working with a group of residents at a local hospital going over insulin dosing: 9 residents answering 10 dosing questions each. The wrong dose was given 65% of the time and 1/2 of those would have caused harm to the patient. Now Novo has put together an …

Read More »

Oct. 26, 2019

I am at the NCPA meeting in San Diego this weekend, and while I was on the plane I was rereading The 4-Hour Body, by Tim Ferriss. In one section of the book he talks about the slow carb diet and delves into how reducing carbs can actually reverse hypertension …

Read More »

Oct. 22, 2019

It has been a dozen years since Dr. Steven Nissen took direct aim at pioglitazone and rosiglitazone, based on his interpretation of cardiac risk factors. The FDA rushed to put severe restriction on their usage and finally in 2010 rosiglitazone, also known as Avandia, was withdrawn from the market. Pioglitazone …

Read More »

Oct. 19, 2019

It has been over 6 years since the FDA approved Invokana as the first SGLT-2 inhibitor for the treatment of diabetes. When it was introduced there was a cautious optimism based on the tremendous amount of press concerning the fear of urinary tract infections. Usage was slow at first but …

Read More »

Oct. 15, 2019

Our former intern, Amber Satz, PharmD Candidate, LECOM School of Pharmacy, was reviewing some info on GLP-1 Analogs and came across a new entry into the class. Efpeglenatide is a new weekly analog from Sanofi. It appears to be as effective as all other weekly’s out there, and it will …

Read More »